Studying how eating fewer calories changes liver response to glucagon in type 2 diabetes
Tests whether eating fewer calories changes liver response to glucagon in type 2 diabetes.
Plain-language title generated from the registry record
Registry title: The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 65 years old?
Source: NCT05499702, who can take part
Where in United States
- Mayo Clinic in RochesterRochester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Adrian Vella
- Trial code
- NCT05499702
- Record updated
- 28 October 2026
- Original description
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.Read full original descriptionShow less
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.
Inclusion: We will recruit up to 20 weight-stable, subjects with type 2 diabetes; BMI ≥ 28 Kg/M2; Diabetes is managed by diet alone or a combination of oral agents.
Exclusion: History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy; Contraindications to MRI (e.g. metal implants, claustrophobia); Active systemic illness or malignancy; Symptomatic macrovascular or microvascular disease; Hematocrit < 35%; TSH < 0.4 or > 5.5; Consumption of > 2 alcohol drinks per day or > 14 per week or a positive AUDIT questionnaire.